UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 2, 2016
ULTRAGENYX PHARMACEUTICAL INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
Delaware |
|
001-36276 |
|
27-2546083 |
||
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
||
|
|
|
|
||||
|
60 Leveroni Court, Novato, California |
|
94949 |
||||
|
(Address of principal executive offices) |
|
(Zip Code) |
||||
Registrant’s telephone number, including area code: (415) 483-8800
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
-1-
On December 2, 2016, Ultragenyx Pharmaceutical Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission to allow for the resale to the public from time to time of up to 352,530 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), held by Takeda Pharmaceutical Company Limited (“Takeda”). Takeda purchased the Shares on November 3, 2016 pursuant to the terms of the Common Stock Purchase Agreement by and between the Company and Takeda, dated June 6, 2016. The Company is not offering any of its shares of common stock for sale to the public pursuant to the Prospectus Supplement and will not receive any of the proceeds from the sale of the Shares by Takeda.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
5.1 |
Opinion of Gibson, Dunn & Crutcher LLP |
|
23.1 |
Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1) |
* * *
-2-
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: December 2, 2016 |
|
|
|
Ultragenyx Pharmaceutical Inc. |
||
|
|
|
|
|
|||
|
|
|
|
|
By: |
|
/s/ Shalini Sharp |
|
|
|
|
|
|
|
Shalini Sharp |
|
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer |
-3-
|
Exhibit No. |
Description |
|
5.1 |
Opinion of Gibson, Dunn & Crutcher LLP |
|
23.1 |
Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1) |
-4-